William W. Tseng, MD

home / authors / william-w-tseng-md

Articles

William W. Tseng, MD, of the University of Southern California

Dr. Tseng on the Goal of the TARPSWG Analysis in Retroperitoneal Sarcoma

William W. Tseng, MD
October 27th 2020

William W. Tseng, MD, discusses the goals of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Read More

William W. Tseng, MD

Dr. Tseng on the Significance of the TARPSWG Analysis in Retroperitoneal Sarcoma

William W. Tseng, MD
October 9th 2020

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Read More

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

Dr. Tseng on the Rationale for the TARPSWG Analysis in Retroperitoneal Sarcoma

William W. Tseng, MD
October 5th 2020

William W. Tseng, MD, discusses the rationale for the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

Read More

Dr. Tseng on Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

Dr. Tseng on Role of Neoadjuvant Systemic Therapy in High-Risk Retroperitoneal Sarcoma

William W. Tseng, MD
June 23rd 2020

William W. Tseng, MD, discusses the potential role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data